PMI (NYSEAMERICAN:PMI) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of PMI (NYSEAMERICAN:PMI) to a hold rating in a research report released on Tuesday morning,Zacks.com reports.

Separately, HC Wainwright began coverage on PMI in a research note on Monday. They set a “neutral” rating on the stock. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.

PMI Trading Down 3.7%

PMI opened at $0.15 on Tuesday. PMI has a one year low of $0.13 and a one year high of $13.68. The company has a current ratio of 0.75, a quick ratio of 0.72 and a debt-to-equity ratio of 0.01. The firm has a 50-day simple moving average of $0.78.

PMI (NYSEAMERICAN:PMI) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.10) EPS for the quarter. The firm had revenue of $1.15 million during the quarter. On average, analysts expect that PMI will post -0.17 earnings per share for the current year.

PMI News Roundup

Here are the key news stories impacting PMI this week:

• Neutral Sentiment: HC Wainwright reiterated a Neutral stance on PMI while publishing updated estimates across 2026 and 2027, including projected losses in every period and full-year EPS of ($0.17) for FY2026 and ($0.09) for FY2027. PMI analyst coverage
• Neutral Sentiment: The most recent quarterly results also showed PMI remained unprofitable, with the company posting ($0.10) EPS on $1.15 million in revenue, reinforcing concerns about near-term profitability. PMI earnings results
• Negative Sentiment: Multiple analyst forecasts for the next several quarters point to continued losses, which can weigh on investor sentiment and keep pressure on the stock. PMI earnings estimates

PMI Company Profile

Picard Medical Inc is a medical technology company which manufactures and sells the only total artificial heart. Picard Medical Inc is based in TUCSON, Ariz.